Inflammatory Bone Destruction
Inflammatory Bone Destruction - Related Videos
08:49
Models of Bone Metastasis
0 Views •
Cited by 115 •
2012
Animal models are frequently utilized to study cancer metastasis to bone. In this protocol we will describe two common methods of tumor inoculation for bone metastasis studies and briefly describe some of the analyses utilized to monitor and quantify these models.
08:24
Introduction to the Ultrasound Targeted Microbubble Destruction Technique
0 Views •
Cited by 19 •
2011
Ultrasound Targeted Microbubble Destruction (UTMD) can be used to direct site-specific delivery of bioactive molecules, including therapeutic genes, to target organs accessible to ultrasound, such as the heart and liver1-6.
01:12
Non-destructive Tests for Concrete Strength
0 Views •
2024
The rebound hammer test, also known as the Schmidt hammer test, is a non-destructive technique for evaluating the hardness of concrete and, indirectly, the strength of concrete. It operates on the principle that the rebound of a spring-driven mass from a concrete surface correlates to the surface's hardness. The device comprises a mass within a tubular housing, a spring mechanism, and a plunger that strikes the concrete. Upon release, the energy imparted to the mass by the spring causes it to...
06:45
Automated Joint Space Detection Improves Bone Segmentation Accuracy
0 Views •
2025
The development of an automated joint space detection workflow enabled high-throughput segmentation of distinct murine hindpaw bones with >98% accuracy in wild-type animals. Flexible application to forepaws and paws with inflammatory-erosive arthritis was achieved, but with deprecated performance that warrants further optimization in future studies using publicly available data.
12:43
On-Chip Endothelial Inflammatory Phenotyping
0 Views •
Cited by 3 •
2012
Microfluidic flow chambers etched by photolithography and fabricated from PDMS are applied to probe functional outcomes associated with EC dysfunction and inflammation. In a representative experiment, the ability of differential shear stress to modulate monocytic cell adhesion to cytokine activated EC monolayers is demonstrated.
FAQs
The central molecular link is increased RANKL signaling. Microbial products and inflammatory cytokines, particularly tumor necrosis factor, interleukin-1, and interleukin-6, amplify this signaling during sustained immune activation. RANKL then promotes osteoclast differentiation and activity, connecting an inflammatory stimulus to greater bone resorption rather than treating immune activation and skeletal damage as separate events.
Bone loss can reflect both increased removal and inadequate replacement. Inflammatory conditions can impair osteoblast-mediated repair while cytokine-driven RANKL signaling activates osteoclasts. This combination shifts skeletal tissue toward net loss because resorption continues as the capacity to restore damaged bone declines. Studying both processes is therefore important when evaluating inflammatory damage.
Sustained immune activation continually exposes skeletal tissue to microbial products and inflammatory cytokines. Repeated stimulation maintains RANKL-associated osteoclast differentiation and resorption, while inflammation can continue to interfere with osteoblast-mediated repair. This persistence helps explain why chronic infections and inflammatory diseases can produce progressive bone damage rather than a short-lived change in remodeling.
Osteomyelitis and periodontal disease are prominent contexts because they connect immune activation with skeletal tissue damage during infection-associated inflammation. Other chronic inflammatory conditions can also reveal how cytokines and RANKL signaling affect bone. Comparing these settings helps investigators identify shared pathways while accounting for the distinct inflammatory environments surrounding affected tissue.
Researchers can use the pathways connecting microbial products, cytokines, RANKL signaling, osteoclast activity, and impaired repair as a framework for biomarker development. Signals that reflect immune activation or bone-resorptive activity may help characterize disease-related tissue damage. Such markers could support investigation of disease progression and evaluation of strategies intended to limit bone loss.
A useful intervention must reduce pathological bone loss without compromising antimicrobial defense. The same inflammatory environment may reflect an immune response to infection, so suppressing it indiscriminately could create an undesirable balance between skeletal protection and host defense. Research therefore focuses on defining immune pathways that can be targeted while preserving essential antimicrobial activity.